ABSTRACT
Staphylococcus aureus is a common threat to hospitalized patients and is responsible for a variety of infections, ranging from superfi cial skin and soft tissue infections to toxic shock syndrome and severe systemic infections (1) . Furthermore, methicillinresistant Staphylococcus aureus (MRSA) has become a major concern in the hospital environment. Methicillin resistance in S. aureus is conferred by penicillin binding protein 2a (PBP2a), encoded by the mecA gene located on a genetic element called the staphylococcal cassette chromosome (SCC) (2) . Staphylococcus aureus produce a remarkable range of secreted virulence factors that facilitate their pathogenicity, such as toxic shock syndrome toxin-1 (TSST-1) (1) . TSST-1 is known as a superantigen for its ability to non-specifi cally stimulate activation of T lymphocytes (3) . TSST-1 is encoded by tstH, which is located on the bacterial chromosome within a 15.2-kb mobile genetic element; it has been associated with several acute or chronic human diseases, including toxic shock syndrome (TSS) (3) . TSS is an acute and potentially fatal illness characterized by high fever, diffuse erythematous rash, desquamation of the skin 1 to 2 weeks after the onset (if not fatal before this time), hypotension, and involvement of three or more organ systems (3) .
Characterizing the differences in the pathogenicity and virulence patterns of MRSA and methicillin-susceptible S. aureus (MSSA) could help manage hospitalization time and mortality (1) (3) . A recent study of clinical MRSA isolates from, Shiraz, Iran demonstrated the prevalence of several toxin genes, including tst (1) . The aim of this study was to compare the prevalence of the tst gene in clinical MSSA and MRSA isolates in Shiraz, a major city in southwest Iran.
This cross-sectional study was conducted in 2012-2013 at the Namazee and Faghihi hospitals in Shiraz. These are major tertiary care hospitals with 1,000 beds; both are affi liated with the Shiraz University of Medical Science. Samples included 345 S. aureus isolates obtained from various clinical specimens such as blood, pus, wounds, and urine. Specimens were collected from different wards in each hospital. Duplicate isolates and specimens labeled as 'outpatient' were excluded. The isolates were identifi ed as S. aureus by conventional microbiologic procedures (colony morphology, Gram staining, catalase activity, growth on mannitol salt agar, DNase test, and tube coagulase). Preliminary identifi cation of MRSA and MSSA was based on resistance to cefoxitin (30μg) (MAST company, United Kingdom) by the disc diffusion assay according to Clinical and Laboratory Standards Institute (CLSI) guidelines (4) . Staphylococcus aureus ATCC 25923 (an MSSA) was used as the control for antibacterial susceptibility testing. Confi rmed isolates were stored at -80°C for long-term preservation. Genomic deoxyribonucleic acid (DNA) was extracted by using the small-scale phenol-chloroform extraction method (5) . DNA concentrations were determined by spectrophotometry at A 260 based on µg/mL concentration. In this study, DNA sample quantities ranged from 10 to 1,000ng. DNA was preserved at -20°C. The phenotypically confi rmed MRSA isolates were subsequently tested for the presence of mecA as described by Zhang et al. (6) . All MRSA and MSSA isolates were also assayed for the presence of the tst gene by using previously described primers (7) . MRSA reference strains JCSC/4469 were used as positive mecA and tst gene controls. Reference strains were kindly provided by Professor Alborzi Clinical Microbiology Research Center, Shiraz, Iran. Polymerase chain reaction (PCR) amplifi cations were performed using a DNA Thermal Figure 1 . The distribution of tst among the S. aureus isolates is presented in Table 1 . Despite the high frequency of tst in the MSSA versus MRSA isolates, statistical analysis showed no signifi cant differences. The prevalence of toxin genes in different clinical specimens is shown in Table 2 . The main clinical sources of tst were sputum, wound, and skin specimens, each of which yielded 11 positive samples. Ear specimens showed 2 out of 2 samples were positive for the tst gene. The tst gene distribution was more variable among clinical specimens in MSSA isolates, since tst was detected in 10 different specimens. The tst gene was detected in more isolates from Faghihi hospital (n=33) than from Namazee (n=20), but the difference did not reach statistical signifi cance. In this study of southwest Iranian hospitals, we identifi ed 53 (15.4%) isolates positive for the gene encoding TSST-1. In the north (Tehran) and north-east (Tabriz) of Iran, the tst-positive rates are 12.8% and 17.4%, respectively (8) (9) . Studies in Turkey and Colombia showed tst-positive rates of 14.2% and 18% (10) (11) .
The frequency of the tst gene was numerically higher in our MSSA isolates than in the MRSA isolates (18.1% vs. 11.6%), although the difference was not signifi cant. Jiménez et al. also showed a greater frequency of tst in MSSA versus MRSA isolates from pediatric patients (11) . Sila et al (12) . from the Czech Republic reported the 6% of tst-carrying MSSA were more virulent than 2% of tst-carrying MRSA (12) .
Although we identifi ed no signifi cant overall difference in the prevalence of tst gene between MRSA and MSSA isolates. We did observe a signifi cant difference in isolates from blood, with 20% of MRSA versus 7.7% of MSSA isolates carrying the tst gene. Peck et al (13) . reported that TSST-1 producing MRSA isolates were more prevalent in blood samples (13) .
Although we identifi ed sputum, wounds, and skin as three major sources of TSST-1 producing isolates, wounds are the most common source for isolation of TSST-1 producing S. aureus. Teyhoo et al. from Iran and Daghistani et al. from Jordan reported substantial rates of tst-harboring S. aureus isolates from wound samples (9) (14) .
In this study, the skin was most frequently associated with tst-carrying isolates, with twice the rate of detection (44%) in comparison to sputum and wounds. This high rate of TSST-1 producing S. aureus isolates may be considered a risk factor for vulnerable groups such as newborns and patients with atopic dermatitis (15) . As virulence factors accelerate colonization and invasion through minor breaks in the skin and mucus membranes, the subsequent spread of TSST-1 producing S. aureus to the bloodstream could have a critical infl uence on clinical outcomes (14) .
MRSA isolates are known to be more antibiotic resistant than MSSA isolates and antimicrobial resistance may generally be considered an important factor for the clinical outcome of S. aureus infection as well (11) . However, a higher rate of TSST-1 carrying isolates was detected among MSSA isolates compared to that for MRSA isolates, although the difference was not statistically signifi cant in our study. So, MSSA isolates might be more virulent in term of TSST-1 than MRSA isolates. We suggest the most dangerous S. aureus are not necessarily those with the most antibiotic resistance. Antibiotic resistance is thought to impose a fi tness cost associated with a reduction in toxin production (3) (11) , it is not surprising that our MRSA isolates showed less toxin rate.
In summary, we have shown a frequency of up to 15% tst-positivity in MSSA and MRSA isolates and suggesting methicillin resistance has no effect on acquisition of the virulence gene. We conclude that the risk of infection with S. aureus should not be assigned only based on methicillin resistance.
